Stem cell tumorigenicity in Balb/c nude mice

doi:10.3969/j.issn.2095-4344.2014.06.011

Abstract

Abstract:

BACKGROUND:Stem cell tumorigenicity is a practical issue concerning stability in the clinical application of stem cells. Therefore, it is particularly important to clear whether stem cells have tumorigenic ability or not. Nude mice occupy an increasingly important position in oncology, immunology, and safety evaluation of drugs and biological products.

OBJECTIVE: To observe the tumorigenicity of neural stem cells and mesenchymal stem cells in Balb/c nude immunodeficient mice.

METHODS: Balb/c nude mice were randomly divided into control group, negative group, positive group, neural stem cell group and mesenchymal stem cell group. HepG-2 cells, RPE cells, passage 4 neural stem cells and mesenchymal stem cells were injected subcutaneously into nude mice from different groups, respectively. After 12 weeks of injection, anatomical observation was performed to detect the tumor formation in the transplantation site. Meanwhile, soft agar colony formation assay was applied to investigate neural stem cell and mesenchymal stem cell clone in vitro.

RESULTS AND CONCLUSION:After 12 weeks of injection, the tumorigenicity study results showed that no tumor developed in the transplantation site in the control group, negative group, neural stem cell group and mesenchymal stem cell group. Histopathologic examinations also showed no abnormality in these groups. Soft agar colony formation assay showed in soft agar resistance medium, neural stem cells and mesenchymal stem cells did not exhibit clone ability. These findings indicate that neural stem cells and mesenchymal stem cells undergoing short-term passages have no tumorigenic growth.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: stem cells, neural stem cells, mesenchymal stem cells, carcinogenicity tests, retinal pigment epithelium

CLC Number:

R394.2

Nie De-zhi, Wan Ying, Ben Liang, Wang Ying-jun, Liu Xiang-zhu, Wang Li-hui, Li Chao, Zhang Shi-dong. Stem cell tumorigenicity in Balb/c nude mice[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(6): 888-893.

Figures/Tables 3

References

[1] Fernandez Tde S, de Souza Fernandez C, Mencalha AL. Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Res Int. 2013; 2013:430290.

[2] Greco SJ, Rameshwar P. Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. Ther Deliv. 2012;3(8):997-1004.

[3] Gu E, Chen WY, Gu J, et al. Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics. 2012; 2(4):335-345.

[4] Djouad F, Bouffi C, Ghannam S, et al. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5:392-399.

[5] Teoh HK, Cheong SK. Induced pluripotent stem cells in research and therapy, Malays J Pathol. 2012;34(1):1-13.

[6] Carroll SH, Ravid K. Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors. Expert Rev Mol Med. 2013;15:e1.

[7] Sensebé L, Fleury-Cappellesso S. Biodistribution of Mesenchymal Stem/Stromal Cells in a Preclinical Setting. Stem Cells Int. 2013;2013:678063.

[8] Dorronsoro A, Fernández-Rueda J, Fechter K, et al.Human Mesenchymal Stromal Cell-Mediated Immunoregulation: Mechanisms of Action and Clinical Applications. Bone Marrow Res. 2013;2013:203643.

[9] Wei X, Yang X, Han ZP, et al.Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747-754.

[10] Stochaj U, Kodiha M, Shum-Tim D, et al. Implications of multipotent mesenchymal stromal cell aging. Regen Med. 2013;8(2):211-222.

[11] Yao J, Mu Y, Gage FH. Neural stem cells: mechanisms and modeling. Protein Cell. 2012;3(4):251-261.

[12] Kohman RA, Rhodes JS. Neurogenesis, inflammation and behavior. Brain Behav Immun. 2013;27(1):22-32.

[13] Gincberg G, Arien-Zakay H, Lazarovici P, et al. Neural stem cells: therapeutic potential for neurodegenerative diseases. Br Med Bull. 2012;104:7-19.

[14] Tan J, Meng Y, Huang S, et al.Therapeutic gene products delivery by neuron stem cells. Curr Pharm Biotechnol. 2012; 13(12):2427-2431.

[15] Andressen C. Neural stem cells: from neurobiology to clinical applications. Curr Pharm Biotechnol.2013;14(1):20-28.

[16] Ding DC, Lin CH, Shyu WC, et al. Neural stem cells and stroke. Cell Transplant. 2013;22(4):619-630.

[17] English D, Sharma NK, Sharma K, et al. Neural stem cells-trends and advances. J Cell Biochem. 2013;114(4): 764-772.

[18] Neirinckx V, Coste C, Rogister B, et al. Concise review: adult mesenchymal stem cells, adult neural crest stem cells, and therapy of neurological pathologies: a state of play. Stem Cells Transl Med. 2013; 2(4):284-296.

[19] WHO Technical Report Series[R]. Annex 1: Requirements for the used of animal cells as in vitro substrated for the production of biologicals. 1998: 878.

[20] FDA. Points toconsider in the characterization of cell linesused to produce biologicals[S]. 1993.

[21] 中国药典.三部[S].北京: 化工业出版社, 2010: 14-17.

[22] 张赛,刘振林,刘晓智,等.hTERT永生化脐带间充质干细胞的致瘤性研究[J].中国神经精神疾病, 2008, 34(3): 171-173.

[23] 林戈,卢光琇.干细胞概述[J].生命科学,2006,18(4): 313-317.

[24] 李凌松,路艳艳.神经干细胞及帕金森病的细胞治疗[J].北京大学学报(医学版),2002,34(5):499-505.

[25] 屈红林,彭瑞. 神经干细胞研究现状及在运动医学领域中的应用[J].中国组织工程研究与临床康复,2008, 12(25):4941-4944.

[26] 庞永刚,崔彭城,陈文弦,等.人骨髓间质干细胞作为骨、软骨组织工程种子细胞的实验研究[J].细胞与分子免疫学杂志,2004, 20 (3): 306-309.

[27] Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105(4): 1815-1822.

[28] Jiang WH, Ma AQ, Zhang YM, et al. Migration of intravenously grafted mesenchymal stem cells to injured heart in rats. Acta Physiological Sinica. 2005;57(5):566-572.

[29] Zhu D, Wan X, Huang H, et al. Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells. Oncol Rep. 2014; 31(2):727-736.

[30] Sato Y. In vitro tumorigenicity tests for process control of health care products derived from human induced pluripotent stem cells. Yakugaku Zasshi. 2013;133(12):1381-1388.

[31] de Almeida PE, Ransohoff JD, Nahid A, et al. Immunogenicity of pluripotent stem cells and their derivatives. Circ Res. 2013; 112(3):549-561.

[32] Kuroda T, Yasuda S, Sato Y. Tumorigenicity studies for human pluripotent stem cell-derived products. Biol Pharm Bull. 2013;36(2):189-192.

[33] Kobayashi Y, Okada Y, Itakura G, et al. Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One. 2012; 7(12): e52787.

[34] Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer.2011;11:268-277.

[35] Kooreman NG, Wu JC. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J R Soc Interface. 2010;7(Suppl 6):S753-763.

[36] Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature.2011;474:212-215.

[37] Shen G, Cong XQ. The tumorigenicity of immortalized cells differentiated from mouse embryonic stem cells. Zhonghua Zheng Xing Wai Ke Za Zhi. 2012;28(1):33-39.

[38] Okada Y, Okano H. Evaluation of human iPS cells by neural differentiation and tumorigenicity. Rinsho Shinkeigaku. 2011; 51(11):1079-1080.

[39] Dressel R. Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells. Semin Immunopathol. 2011;33(6):573-591.

[40] Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 1964;24:1544-1551.

[41] Shamblott MJ, Axelman J, Wang SP, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA. 1998,95(23):13726-13731.

[42] Hua JL, Qiu BP, Zhu HJ, et al. Multipotent mesenchymal stem cells (MSCs) from human umbilical cord: Potential differentiation of germ cells. Afric J of Biochem Res. 2011;5(4): 113-123.

[43] 李六金,李秦,施新猷,等.五种动物传代细胞系对裸鼠的致瘤性[J]. 第四军医大学学报, 2000, 21(6):738-740.